These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38196926)
1. Blood product use for radiological/nuclear trauma: product development and US regulatory considerations. Silverman TA; Shadiack AM; Hofmeyer KA; Cecere AE; Eisnor DL; Hoffman CM; Loelius SG; Patel A; Homer MJ Trauma Surg Acute Care Open; 2024; 9(Suppl 1):e001123. PubMed ID: 38196926 [TBL] [Abstract][Full Text] [Related]
2. The interagency strategic plan for research and development of blood products and related technologies for trauma care and emergency preparedness 2015-2020. Pusateri AE; Homer MJ; Rasmussen TE; Kupferer KR; Hoots WK Am J Disaster Med; 2018 Summer; 13(3):181-194. PubMed ID: 30629273 [TBL] [Abstract][Full Text] [Related]
3. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016. Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in medical countermeasure development against acute radiation exposure based on the US FDA animal rule. MacVittie TJ; Farese AM J Radiol Prot; 2021 Nov; 41(4):. PubMed ID: 34433144 [TBL] [Abstract][Full Text] [Related]
8. An update on romiplostim for treatment of acute radiation syndrome. Singh VK; Seed TM Drugs Today (Barc); 2022 Mar; 58(3):133-145. PubMed ID: 35274632 [TBL] [Abstract][Full Text] [Related]
9. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. Wallach JD; Ross JS; Naci H Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509 [TBL] [Abstract][Full Text] [Related]
11. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. Singh VK; Newman VL; Seed TM Cytokine; 2015 Jan; 71(1):22-37. PubMed ID: 25215458 [TBL] [Abstract][Full Text] [Related]
12. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents. Singh VK; Romaine PL; Newman VL; Seed TM Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458 [TBL] [Abstract][Full Text] [Related]
13. Scientific research and product development in the United States to address injuries from a radiation public health emergency. DiCarlo AL J Radiat Res; 2021 Sep; 62(5):752-763. PubMed ID: 34308479 [TBL] [Abstract][Full Text] [Related]
14. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. Singh VK; Garcia M; Seed TM Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406 [TBL] [Abstract][Full Text] [Related]
15. Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule. Fed Regist; 1991 Nov; 56(225):58758-9. PubMed ID: 10115699 [TBL] [Abstract][Full Text] [Related]